Preclinical characterization of ARX517, a next-generation anti-PSMA antibody drug conjugate for the treatment of metastatic castration-resistant prostate cancer

被引：2
|
作者：
Skidmore, Lillian
Mills, David
Kim, Ji Young
Shastri, Prathap
Knudsen, Nick A.
Steen, Jeff
Nelson, Jay
Buechler, Ying
Tian, Feng
Zhang, Shawn
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-3997
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3997
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody-Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer
    Skidmore, Lillian K.
    Mills, David
    Kim, Ji Young
    Knudsen, Nick A.
    Nelson, Jay D.
    Pal, Manoj
    Wang, Jianing
    Kedar, G. C.
    Gray, Michael J.
    Barkho, Wisam
    Shastri, Prathap Nagaraja
    Ramprasad, Mysore P.
    Tian, Feng
    O'Connor, Daniel
    Buechler, Ying J.
    Zhang, Shawn Shao-Hui
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (12) : 1842 - 1853
  • [2] Evaluation of ARX517: A next-generation anti-PSMA antibody drug conjugate for prostate cancer treatment, in preclinical enzalutamide-resistant and enzalutamide-sensitive pharmacology models and in toxicology models
    Zhang, S.
    Mills, D.
    Kim, J. Y.
    Knudsen, N.
    Nelson, J.
    Buechler, Y.
    Skidmore, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S199 - S199
  • [3] ARX517: A next generation anti-PSMA antibody drug conjugate (ADC) demonstrates notable stability and pharmacokinetic (PK) profile in the ARX517 phase I clinical trial (APEX-01)
    Tagawa, S. T.
    Shen, J.
    Skidmore, L.
    Nelson, J.
    Pachynski, R.
    Zhang, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S990 - S990
  • [4] The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment
    Hovelson, Daniel H.
    Tomlins, Scott A.
    CANCER JOURNAL, 2016, 22 (05): : 357 - 361
  • [5] The prevalence and prognosis of next-generation therapeutic targets in metastatic castration-resistant prostate cancer
    Pan, Jian
    Zhao, Jinou
    Ni, Xudong
    Gan, Hualei
    Wei, Yu
    Wu, Junlong
    Zhang, Tingwei
    Wang, Qifeng
    Freedland, Stephen J.
    Wang, Beihe
    Song, Shaoli
    Ye, Dingwei
    Liu, Chang
    Zhu, Yao
    MOLECULAR ONCOLOGY, 2022, 16 (22) : 4011 - 4022
  • [6] Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC): a Phase 1 Trial in Castration-Resistant Metastatic Prostate Cancer (mCRPC)
    Petrylak, D.
    Kantoff, P.
    Mega, A.
    Stephenson, J.
    Vogelzang, N.
    Fleming, M.
    Blattman, S.
    Stambler, N.
    D'Ambrosio, P.
    Israel, R. J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 75 - 75
  • [7] Combining next-generation hormonal therapy with PARP inhibition in metastatic castration-resistant prostate cancer
    Abida, Wassim
    Attard, Gerhardt
    LANCET, 2023, 402 (10398): : 266 - 267
  • [8] Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
    Lavaud, Pernelle
    Dumont, Clement
    Thibault, Constance
    Albiges, Laurence
    Baciarello, Giulia
    Colomba, Emeline
    Flippot, Ronan
    Fuerea, Alina
    Loriot, Yohann
    Fizazi, Karim
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [9] Preclinical characterization of ARX305, a next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers
    Skidmore, Lillian
    Zhu, Jingjing
    Mills, David
    Jin, Ting
    Li, Suqin
    Tatsukawa, Keith
    Knudsen, Nick A.
    Gong, Liying
    Nelson, Jay
    Cox, Kari
    Hewet, Amha G.
    Wang, Jianing
    Buss, Tim
    Tian, Feng
    Xia, Gang
    Zhang, Shawn
    CANCER RESEARCH, 2023, 83 (07)
  • [10] Preclinical characterization of ARX305: A next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers
    Skidmore, L.
    Mills, D.
    Kim, J. Y.
    Tatsukawa, K.
    Knudsen, N.
    Nelson, J.
    Wang, J.
    Zhang, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S208 - S208
12345